Activity

In 2008, the GEC ESTRO Gyn network launched the first multiinstitutional, observational, and prospective international study on MRI-guided brachytherapy in locally advanced cervical cancer patients (EMBRACE-I). EMBRACE-I was followed by EMBRACE-II from 2016 and ongoing. Among the aims of the EMBRACE studies are to benchmark morbidity outcomes and develop dose-volume effects and predictive models for morbidity. The EMBRACE studies collect both physician (CTCAE v.3) and patient (EORTC QLQ-C30/CX24) reported outcomes, including baseline information, in a regular follow-up schedule. The EMBRACE studies feature high numbers of patients (EMBRACE-I N = 1416, EMBRACE-II N = 1500 expected) enrolled from many institutions worldwide (EMBRACE-I n = 23, EMBRACE-II n = 45). This large-scale multiinstitutional approach offers a unique opportunity to investigate and develop new strategies for improving the quality of assessment and reporting of morbidity. This report presents an overview of the challenges and pitfalls regarding the assessment and reporting of morbidity encountered during more than a decade of development and research activities within the EMBRACE consortium. This includes the recognition and evaluation of inconsistencies in the morbidity assessment, and consequently, the provision of assistance and training in the scoring procedure to reduce systematic assessment bias. In parallel, a variety of methodological approaches were tested to comprehensively summarize morbidity outcomes, and a novel approach was developed to refine dose-effect models and risk factor analyses. The purpose of this report is to present an overview of these findings, describe the learning process, and the strategies that have consequently been implemented regarding educational activities, training, and dissemination.

Infrazygomatic crest (IZC) dimension is an important factor in the safety and stability of bone screws. The dimension is known to vary according to the dimensions of the maxillary sinus, which in turn depends on the vertical facial skeletal pattern.

The objective of the study was to compare the infrazygomatic crest thickness (IZC) above the mesiobuccal root of the first and second maxillary molar in different vertical skeletal patterns.

This was a retrospective study conducted in Saveetha Dental College, Chennai. Cone beam computed tomography (CBCT) and lateral cephalograms of 36 subjects were collected and divided into 3 groups (12 subjects in each group) depending on their vertical skeletal pattern, namely normal, low and high angle. Vertical skeletal pattern was assessed using lateral cephalogram whereas IZC thickness was measured using CBCT. GDC-0941 Mann Whitney U test was done to compare the bone thickness in the right and left sides and also to compare the same above the mesiobuccal root of the first and second molar. Kruskal Wallis and post hoc tests were done to compare bone thickness among the three groups. P-value was set at 0.05 for all the analysis.

Significant difference in IZC bone thickness above the first molar region was noted between high angle and average angle groups (P-value 0.001) and high angle and low angle (P-value 0.001). Above the second molar region, a significant difference was seen between high angle and average angle groups (P-value 0.001). Significant difference in bone thickness was also observed among the first molar and second molar region in all the three groups (P-value<0.05).

IZC thickness was the least in high-angle subjects. Clinically, it is desirable to place the IZC screw above the mesiobuccal root of the maxillary second molar especially in high-angle subjects.

IZC thickness was the least in high-angle subjects. Clinically, it is desirable to place the IZC screw above the mesiobuccal root of the maxillary second molar especially in high-angle subjects.The increased availability of new cancer treatments in recent years has led to improved prognosis and increased life expectancy for cancer patients, but at the expense of increased cardiovascular risk. For this reason, multidisciplinary teams need to be formed for the joint evaluation of these patients to optimise the cardiovascular health and overall survival of these patients and minimise interruptions to onco-haematological treatments. A wide range of cardiovascular toxicities are associated with the various cancer treatments. The structured control of cardiovascular risk before, during and after oncological treatment will enable strategies for the prevention, early detection and early treatment of cardiotoxicities.

This study aimed to compare the safety and efficacy of clarithromycin-naproxen-oseltamivir combination therapy to that of oseltamivir therapy alone in hospitalized pediatric influenza patients.

This prospective, single-blind study included children aged 1-18 years hospitalized with influenza, in MacKay Children’s Hospital, Taiwan, between December 2017 and December 2019. The primary outcomes were the time to defervescence and decrease of the Pediatric Respiratory Severity Score (PRESS) during hospitalization. The secondary outcomes were serial changes in virus titers, measured using real-time polymerase chain reaction.

Fifty-four patients were enrolled (28 in the control group and 26 in the combination group) in total. There were no differences in the patients’ baseline characteristics between the groups. The time to defervescence was significantly shorter in the combination group than the oseltamivir group (13.2h vs. 32.1h, p=0.002). The decrease in the virus titer from days 1-3 (log Δ13) was more pronounced in the combination group than the oseltamivir group. (39% vs. 19%, p=0.001). There were no differences in adverse effects such as vomiting, diarrhea, and abdominal pain during the study or within 30 days after antiviral therapy.

The clarithromycin-naproxen-oseltamivir combination group experienced a more rapid defervescence and a more rapid decline of influenza virus titer than the group treated with oseltamivir alone. Further consideration should be given to whether the overall benefits of combination therapy in hospitalized pediatric influenza patients outweigh the risks.

The clarithromycin-naproxen-oseltamivir combination group experienced a more rapid defervescence and a more rapid decline of influenza virus titer than the group treated with oseltamivir alone. Further consideration should be given to whether the overall benefits of combination therapy in hospitalized pediatric influenza patients outweigh the risks.